While unprofitable companies may collapse due to cash burn, Lexeo Therapeutics (NASDAQ:LXEO) has a healthy cash balance, enough to sustain operations for 3.5 years. Despite revenue challenges, the company's reduced cash burn indicates steady business development.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing